Weighing the Risks: Vivus View of Regulatory Risks in Qnexa Reprise

A good-news press release from Vivus on the resubmission and acceptance of its application to FDA for the weight-loss drug Qnexa contains an unusually long and descriptive list of the risks involved in the application. This more than boiler-plate “forward-looking” statement adds new interest to the sport of footnote-analysis.

Long-term investors in Vivus Inc. are a patient group. They have learned to ride the thick and thin times of a trying regulatory development for the company’s Qnexa weight-loss combo (phentermine and topiramate).

They experienced the good times in early 2010 when Qnexa moved to the front of the pending weight-loss applications Also...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards